Early-Life Height Attainment in Cystic Fibrosis Is Associated with Pulmonary Function at Age 6 Years
Don B Sanders1, James E Slaven2, Karen Maguiness1
1Division of Pulmonology, Allergy and Sleep Medicine, Department of Pediatrics, and.
Insights
Maintaining height-for-age (HFA) above the 50th percentile in early childhood is linked to better lung function in children with cystic fibrosis (CF). This study highlights HFA as a key indicator for respiratory health in CF patients.
Area of Science:
- Pediatric Pulmonology
- Cystic Fibrosis Research
- Growth and Development
Background:
- Early-life weight for age and body mass index (BMI) are known predictors of lung disease in cystic fibrosis (CF).
- The association between height-for-age (HFA) percentiles and respiratory morbidity in early childhood CF is less understood.
- Understanding growth trajectories is crucial for predicting long-term health outcomes in children with CF.
Purpose of the Study:
- To investigate the association between changes in height-for-age (HFA) percentiles during the first six years of life and pulmonary function.
- To determine if early-life HFA trajectories predict lung function (FEV1) at ages 6-7 years in children with CF.
Main Methods:
- Retrospective longitudinal cohort study using the CF Foundation Patient Registry (2003-2010 births).
- Analysis of annualized HFA changes categorized into distinct trajectories.
- Multivariable analysis of covariance models to assess the relationship between HFA trajectories and percent-predicted forced expiratory volume in 1 second (FEV1) at age 6-7 years.
Main Results:
- A cohort of 5,388 children with CF met the inclusion criteria.
- Children consistently maintaining HFA above the 50th percentile demonstrated significantly higher percent-predicted FEV1 at ages 6-7 years.
- Decreases in HFA by ≥10 percentile points were associated with lower FEV1, with a correlation noted between nadir HFA and FEV1.
Conclusions:
- Consistently high HFA (above 50th percentile) in early childhood is associated with optimal pulmonary function in school-aged children with CF.
- While maintaining BMI above the 50th percentile is important, HFA trajectory is a critical, independent marker for evaluating nutritional status and predicting respiratory outcomes.
- Monitoring HFA trends provides valuable insights into respiratory health trajectories in pediatric CF patients.
Abstract:
Rationale: In contrast to the well-described association between early-life weight for age, body mass index (BMI), and later lung disease in people with cystic fibrosis (CF), the relationship between height-for-age (HFA) percentiles and respiratory morbidity is not as well-studied. We hypothesized that changes in HFA in children with CF in the first 6 years of life would be associated with pulmonary function at the age of 6-7 years. Objectives: To determine if an association exists between changes in HFA in early life and pulmonary function in school-aged children with CF. Methods: We performed a retrospective longitudinal cohort study of children with CF followed in the CF Foundation Patient Registry who were born between 2003 and 2010, had CF diagnosed before the age of 2 years, and were followed through at least the age of 7 years. Changes in annualized HFA were classified into mutually exclusive categories. Multivariable analysis of covariance models were used to test for an association between the percent-predicted forced expiratory volume in 1 second (FEV1) at the age of 6-7 years and height-trajectory categories. Results: There were 5,388 eligible children in the CF Foundation Patient Registry. The median (interquartile range) HFA at the age of 6-7 years was in the 39.5th (17.2th-64.9th) percentile. The mean (95% confidence interval) FEV1% predicted at the age of 6-7 years was 95.6% (95.1-96.1%). In a multivariable regression model, the mean (95% confidence interval) FEV1% predicted was higher for children with HFA that was always above the 50th percentile (97.8% [96.3-99.4%]) than for children whose height had been below the 50th percentile for at least 1 year and increased by ≥10 percentile points (95.1% [93.7-96.6%]), was stable (94.3% [92.8-95.7%]), or decreased by ≥10 percentile points (95.7% [94.2-97.3%]). The association between HFA categories and FEV1% predicted was not affected by adding the mean annualized BMI percentile at the age of 6-7 years to the regression model. Among those with HFA that decreased by ≥10 percentile points, there was a correlation between the nadir annualized HFA percentile and the FEV1% predicted at the age of 6-7 years. Conclusions: Children with CF with HFA that is always above the 50th percentile have the highest pulmonary function at the age of 6-7 years. Maintaining a BMI above the 50th percentile remains an important achievable goal for children with CF but is not the sole marker that should be examined in evaluating nutrition.
More Related Videos
07:38Design and Development of a Model to Study the Effect of Supplemental Oxygen on the Cystic Fibrosis Airway Microbiome
Published on: August 3, 2021
08:00Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study
Published on: April 11, 2018
Related Concept Videos
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
Cystic Fibrosis: Management
Sinus disease and chronic...
Nature and Nurture
Pulmonary Function Tests
Pulmonary Function Tests are crucial diagnostic tools for assessing respiratory function, particularly in patients with chronic respiratory disorders. They comprehensively evaluate lung volumes, ventilatory function, breathing mechanics, diffusion, and gas exchange. These tests help diagnose pulmonary diseases and play a significant role in monitoring disease progression, evaluating disability, and assessing response to therapy.
PFTs involve using a spirometer, a...
Signs of Puberty
Pharmacokinetics in Pediatric Patients: Drug Metabolism
